Biologicals for the treatment of systemic lupus erythematosus?

Annals of Medicine

Volumn 44, Issue 3, 2012, Pages 225-232

  Gunnarsson, Iva ^a   Van Vollenhoven, Ronald F ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biologics; Systemic lupus erythematosus; Treatment

Indexed keywords

ABATACEPT; ABETIMUS; ALPHA INTERFERON; ATACICEPT; AZATHIOPRINE; BELIMUMAB; BG 9588; CD40 LIGAND; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 6 ANTIBODY; MYCOPHENOLIC ACID; OCRELIZUMAB; PLACEBO; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; TOCILIZUMAB; TORALIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADD ON THERAPY; CANCER EPIDEMIOLOGY; CELL SURVIVAL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; INFECTION; INFLUENZA; LEUKOENCEPHALOPATHY; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; BIOLOGICAL AGENTS; CYTOKINES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84859338406     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.561362     Document Type: Review

References (35)

1. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007;27:461-6.
2. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000;43:1790-800.
3. Jacob CO, McDevitt HO. Tumour necrosis factor-a in murine autoimmune ' lupus ' nephritis. Nature. 1988;331: 356-8. (Pubitemid 18042493)
4. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis. 2004;63:1075-8. (Pubitemid 39120357)
5. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and effi cacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161-9. (Pubitemid 39371992)
6. Aringer M, Houssiau F, Gordon C, Graninger WB, Voll RE, Rath E, et al. Adverse events and effi cacy of TNF-alpha blockade with infl iximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009;48:1451-4.
7. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H, et al. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2000;9:664-71. (Pubitemid 32011791)
8. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785-96.
9. McBride JM, Wallace D, Yao Z, Morimoto A, Jiang J, Maciuca R, et al. Dose-dependent modulation of Interferon regulated genes with in administration of single and repeat doses of rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE (abstract 2072). Arthritis Rheum. 2009;60(Suppl):S775-6.
10. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18:565-70.
11. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary effi cacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010;62:542-52.
12. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B-cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-9. (Pubitemid 39062719)
13. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005;44:1542-5. (Pubitemid 41742472)
14. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007;56:1263-72. (Pubitemid 46608651)
15. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008;67:330-4. (Pubitemid 351281266)
16. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008;35:826-33. (Pubitemid 351747123)
17. Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009;61:482-7.
18. Catapano F, Chaudhry AN, Jones RB, Smith KG, Jayne DW. Long-term effi cacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 2010;25:3586-92.
19. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and effi cacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458-66.
20. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Effi cacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222-33.
21. Furie RA, Looney RJ, Rovin B, Latinis KM, Appel G, Sanchez-Guerrero J, et al. Effi cacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized double-blind phase III LUNAR study. Arthritis Rheum. 2009;60(Suppl 1):S429.
22. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67(Suppl III):64-5.
23. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.
24. Wallace D, Kalunian K, Petri M, Strand V, Killgallen B, Barry A, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIB study. Ann Rheum Dis. 2010;69(Suppl3):558.
25. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168-78
26. Weinstein A, Petri M, Merrill JT, Furie R, Wallace D, et al. Five-year safety and effi cacy experience with belimumab, a BLyS-specifi c inhibitor, in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis. 2010; 69(Suppl3):147.
27. Navarra S, Ilianova E, Bae S, Guzman R, Tanasescu C, Gallacher A, et al. Belimumab, a BLyS-specifi c inhibitor, reduced disease activity, fl ares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. Ann Rheum Dis. 2010;69(Suppl3):555.
28. Looney J. B-cell-targeted therapies for systemic lupus erythematosus. Drugs. 2010;70:529-40.
29. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced Blymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142-50. (Pubitemid 350262342)
30. Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol. 1997;24:314-8. (Pubitemid 27104095)
31. Cardiel MH, Tumlin JA, Furie RA, Wallace DJ, Joh T, Linnik MD. Abetimus sodium for renal fl are in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum. 2008;58:2470-80.
32. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol. 1996;157:3159-64. (Pubitemid 126450078)
33. Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:3251-8. (Pubitemid 35453534)
34. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719-27. (Pubitemid 36302008)
35. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D ' Cruz D, Wallace DJ, et al. The effi cacy and safety of abatacept in patients with non-life-threatening manifestations of SLE: Results of A 12-month exploratory study. Arthritis Rheum. 2010;62:3077-87.